GRADIENT BIOMODELING, LLC

Biotech · Private

Quantum computational platform for drug discovery against tau protein aggregation in Alzheimer's disease

gradientbiomodeling.com →
Grants
$225K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
5
0 granted · 5 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Discovery of New Chemical Entities for Alzheimer's Disease Tauopathy$224,888
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2841VASCULAR BIOSCIENCES, INC.——
2842EXPRESSION THERAPEUTICS, LLC——
2843CinCor Pharma—$143M
2844GRADIENT BIOMODELING, LLC——
2845Solid Biosciences—$109M
2846Lomond Therapeutics——
2847Cardurion Pharmaceuticals—$350M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 5
  • Macrolide Compounds And Their Use In Liver Stage Malaria And Related Diseaseapplication
  • Macrolide Compounds And Their Use In Liver Stage Malaria And Related Diseaseapplication
  • Ergot Derivative Compounds and Its Use in African Sleeping Sickness and Related Diseaseapplication
  • Macrolide Compounds And Their Use In Liver Stage Malaria And Related Diseaseapplication
  • Macrolide Compounds And Their Use In Liver Stage Malaria And Related Diseaseapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.